Accelerated partial breast irradiation: Potential roles following breast-conserving surgery

Cancer Control

Volumn 17, Issue 3, 2010, Pages 191-204

  Biagioli, Matthew C ^a   Harris, Eleanor E R ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BRACHYTHERAPY; BREAST CANCER; BREAST SURGERY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; ERYTHEMA; ESTHETICS; EXTERNAL BEAM RADIOTHERAPY; FAT NECROSIS; HUMAN; INFECTION; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; INTRADUCTAL CARCINOMA; MASTECTOMY; PARTIAL MASTECTOMY; RADIATION DOSE; SEROMA; TREATMENT FAILURE;

EID: 77954986658     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481001700308     Document Type: Article

References (85)

1. Veronesi U, Marubini E, Mariani L, et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol. 2001;12(7):997-1003.
2. Liljegren G, Holmberg L, Bergh J, et al. 10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol. 1999;17(8):2326-2333.
3. Fisher ER, Anderson S, Tan-Chiu E, et al. Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer. 2001;91(8 suppl):1679-1687.
4. Forrest AP, Stewart HJ, Everington D, et al. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. Lancet. 1996;348(9029): 708-713.
5. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227-1232.
6. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med. 1995;333(22):1444-1455.
7. Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20(20):4141-4149.
8. Van de Steene J, Soete G, Storme G. Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link. Radiother Oncol. 2000;55(3):263-272.
9. Van de Steene J, Vinh-Hung V, Cutuli B, et al. Adjuvant radiotherapy for breast cancer: effects of longer follow-up. Radiother Oncol. 2004;72(1):35-43.
10. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet. 2000;355(9217):1757-1770.
11. Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006; 7:467-471.
12. Clark RM, McCulloch PB, Levine MN, et al. Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst. 1992;84(9):683-689.
13. Fletcher GH. Hypofractionation: lessons from complications. Radiother Oncol. 1991;20(1):10-15.
14. Ash DV, Benson EA, Sainsbury JR, et al. Seven-year follow-up on 334 patients treated by breast conserving surgery and short course radical postoperative radiotherapy: a report of the Yorkshire Breast Cancer Group. Clin Oncol (R Coll Radiol). 1995;7(2):93-96.
15. Olivotto IA, Weir LM, Kim-Sing C, et al. Late cosmetic results of short fractionation for breast conservation. Radiother Oncol. 1996;41(1):7-13.
16. Yamada Y, Ackerman I, Franssen E, et al. Does the dose fractiona-tion schedule influence local control of adjuvant radiotherapy for early stage breast cancer? Int J Radiat Oncol Biol Phys. 1999;44(1):99-104.
17. Shelley W, Brundage M, Hayter C, et al. A shorter fractionation schedule for postlumpectomy breast cancer patients. Int J Radiat Oncol Biol Phys. 2000;47(5):1219.
18. Clark RM, Whelan T, Levine M, et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst. 1996;88(22):1659-1664.
19. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypo-fractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6): 513-520.
20. START Trialists' Group, Bentzen SM, Agrawal RK, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098-1107.
21. START Trialists' Group, Bentzen SM, Agrawal RK, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331-341.
22. Vicini FA, Remouchamps V, Kestin L. Role of radiation therapy in stage I and II breast cancer. In: Singletary ES, Robb GL, Hortobagyi GN, eds. Advanced Therapy of Breast Disease. 2nd ed. Hamilton, Ontario, Canada: BC Decker Inc; 2004.
23. Park cc, Mitsumori M, Nixon A, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol. 2000;18(8):1668-1675.
24. Neuschatz AC, DiPetrillo T, Safaii H, et al. Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy. Cancer. 2003;97(1):30-39.
25. Goldstein NS, Kestin L, Vicini F. Factors associated with ipsilateral breast failure and distant metastases in patients with invasive breast carcinoma treated with breast-conserving therapy. A clinicopathologic study of 607 neoplasms from 583 patients. Am J Clin Pathol. 2003;120(4):500-527.
26. Santiago RJ, Wu L, Harris E, et al. Fifteen-year results of breast-conserving surgery and definitive irradiation for Stage I and II breast carcinoma: the University of Pennsylvania experience. Int J Radiat Oncol Biol Phys. 2004;58(1):233-240.
27. Freedman G, Fowble B, Hanlon A, et al. Patients with early stage invasive cancer with close or positive margins treated with conservative surgery and radiation have an increased risk of breast recurrence that is delayed by adjuvant systemic therapy. Int J Radiat Oncol Biol Phys. 1999; 44(5):1005-1015.
28. Smitt MC, Nowels K, Carlson RW, et al. Predictors of reexcision findings and recurrence after breast conservation. Int J Radiat Oncol Biol Phys. 2003;57(4):979-985.
29. Goldstein NS, Ferkowicz M, Kestin L, et al. Wedge resection margin distances and residual adenocarcinoma in lobectomy specimens. Am J Clin Pathol. 2003;120(5):720-724.
30. Buchholz TA, Kuerer HM, Strom EA. Is partial breast irradiation a step forward or backward? Semin Radiat Oncol. 2005;15(2):69-75.
31. King TA, Bolton JS, Kuske RR, et al. Long-term results of wide-field brachytherapy as the sole method of radiation therapy after segmental mastectomy for T(is,1,2) breast cancer. Am J Surg. 2000;180(4):299-304.
32. Kuske R, Bolton J, Fuhrman G, et al. Wide volume brachytherapy alone for select breast cancers: the ten year experience of the Ochsner Clinic. Int J Radiat Oncol Biol Phys. 2000;48(suppl 3):296. Abstract.
33. Vicini FA, Kestin L, Chen P, et al. Limited-field radiation therapy in the management of early-stage breast cancer. J Natl Cancer Inst. 2003;95(16): 1205-1210.
34. Antonucci JV, Wallace M, Goldstein NS, et al. Differences in patterns of failure in patients treated with accelerated partial breast irradiation versus whole-breast irradiation: a matched-pair analysis with 10-year follow-up. Int J Radiat Oncol Biol Phys. 2009;74(2):447-452.
35. Arthur DW, Koo D, Zwicker RD, et al. Partial breast brachytherapy after lumpectomy: low-dose-rate and high-dose-rate experience. Int J Radiat Oncol Biol Phys. 2003;56(3):681-689.
36. Lawenda BD, Taghian AG, Kachnic LA, et al. Dose-volume analysis of radiotherapy for T1N0 invasive breast cancer treated by local excision and partial breast irradiation by low-dose-rate interstitial implant. Int J Radiat Oncol Biol Phys. 2003;56(3):671-680.
37. Wazer DE, Berle L, Graham R, et al. Preliminary results of a phase I/II study of HDR brachytherapy alone for T1/T2 breast cancer. Int J Radiat Oncol Biol Phys. 2002;53(4):889-897.
38. Berle L, Wazer D, Graham R, et al. Toxicity, local control and cosmesis after interstitial partial breast HDR brachytherapy alone for T1/T2 breast cancer. Radiother Oncol. 2004;71(suppl):74. Abstract.
39. Kaufman SA, DiPetrillo TA, Price LL, et al. Long-term outcome and toxicity in a Phase I/II trial using high-dose-rate multicatheter interstitial brachytherapy for T1/T2 breast cancer. Brachytherapy. 2007;6(4):286-292.
40. Patel RR, Christensen ME, Hodge CW, et al. Clinical outcome analysis in "high-risk" versus "low-risk" patients eligible for national surgical adjuvant breast and bowel B-39/Radiation Therapy Oncology Group 0413 trial: five-year results. Int J Radiat Oncol Biol Phys. 2008;70(4):970-973.
41. Krishnan L, Jewell WR, Tawfik OW, et al. Breast conservation therapy with tumor bed irradiation alone in a selected group of patients with stage I breast cancer. Breast J. 2001;7(2):91-96.
42. Perera F, Yu E, Engel J, et al. Patterns of breast recurrence in a pilot study of brachytherapy confined to the lumpectomy site for early breast cancer with six years' minimum follow-up. Int J Radiat Oncol Biol Phys. 2003;57(5):1239-1246.
43. Fentiman IS, Deshmane V, Tong D, et al. Caesium(137) implant as sole radiation therapy for operable breast cancer: a phase II trial. Radiother Oncol. 2004;71(3):281-285.
44. Johansson B, Karlsson L, Liljegren G, et al. Pulsed dose rate brachytherapy as the sole adjuvant radiotherapy after breast-conserving surgery of T1-T2 breast cancer: first long time results from a clinical study. Radiother Oncol. 2009;90(1):30-35.
45. Póti Z, Nemeskéri C, Fekésházy A, et al. Partial breast irradiation with interstitial 60CO brachytherapy results in frequent grade 3 or 4 toxicity. Evidence based on a 12-year follow-up of 70 patients. Int J Radiat Oncol Biol Phys. 2004;58(4):1022-1033.
46. Arthur DW, Winter K, Kuske RR, et al. A Phase II trial of brachyther-apy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95-17. Int J Radiat Oncol Biol Phys. 2008;72(2):467-473.
47. Vicini FA, Arthur DW. Breast brachytherapy: North American expe- rience. Semin Radiat Oncol. 2005;15(2):108-115.
48. Kuske RR, Winter K, Arthur DW, et al. Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: toxicity analysis of RTOG 95-17. Int J Radiat Oncol Biol Phys. 2006;65(1):45-51.
49. Ibbott GS, Hanson WF, O'Meara E, et al. Dose specification and quality assurance of Radiation Therapy Oncology Group protocol 95-17; a cooperative group study of iridium-192 breast implants as sole therapy. Int J Radiat Oncol Biol Phys. 2007;69(5):1572-1578.
50. Ott OJ, Hildebrandt G, Potter R, et al. Accelerated partial breast irradiation with multi-catheter brachytherapy: local control, side effects and cosmetic outcome for 274 patients. Results of the German-Austrian multi-centre trial. Radiother Oncol. 2007;82(3):281-286.
51. Polgár C, Sulyok Z, Fodor J, et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. J Surg Oncol. 2002;80(3):121-128; discussion 129.
52. Polgár C, Strnad V, Major T. Brachytherapy for partial breast irradiation: the European experience. Semin Radiat Oncol. 2005;15(2):116-122.
53. Polgár C, Fodor J, Major T, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma: 5-year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69(3): 694-702.
54. Keisch M, Vicini F, Kuske RR, et al. Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2003;55(2):289-293.
55. Evans SB, Kaufman SA, Price LL, et al. Persistent seroma after intraoperative placement of MammoSite for accelerated partial breast irradiation: incidence, pathologic anatomy, and contributing factors. Int J Radiat Oncol Biol Phys. 2006;65(2):333-339.
56. Chao KK, Vicini FA, Wallace M, et al. Analysis of treatment efficacy, cosmesis, and toxicity using the MammoSite breast brachytherapy catheter to deliver accelerated partial-breast irradiation: the William Beaumont Hospital experience. Int J Radiat Oncol Biol Phys. 2007;69(1):32-40.
57. Edmundson GK, Vicini FA, Chen PY, et al. Dosimetric characteristics of the MammoSite RTS, a new breast brachytherapy applicator. Int J Radiat Oncol Biol Phys. 2002;52(4):1132-1139.
58. Wu A, Ulin K, Sternick ES. A dose homogeneity index for evaluating 192Ir interstitial breast implants. Med Phys. 1988;15(1):104-107.
59. Benitez PR, Keisch ME, Vicini F, et al. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg. 2007;194(4):456-462.
60. Benitez PR, Streeter O, Vicini F, et al. Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study. Am J Surg. 2006; 192(4):427-433.
61. Vicini F, Beitsch PD, Quiet CA, et al. Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI). Cancer. 2008;112(4):758-766.
62. Nelson JC, Beitsch PD, Vicini FA, et al. Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial. Am J Surg. 2009;198(1):83-91.
63. Cuttino LW, Keisch M, Jenrette JM, et al. Multi-institutional experience using the MammoSite radiation therapy system in the treatment of early-stage breast cancer: 2-year results. Int J Radiat Oncol Biol Phys. 2008;71:107-114.
64. Haley M, Beriwal S, Heron DE, et al. MammoSite accelerated partial breast irradiation: a single-institution outcomes analysis with 2 years of followup. Brachytherapy. 2009;8(1):9-13.
65. Belkacémi Y, Chauvet MP, Giard S, et al. Partial breast irradiation as sole therapy for low risk breast carcinoma: early toxicity, cosmesis and quality of life results of a MammoSite brachytherapy phase II study. Radiother Oncol. 2009;90(1):23-29.
66. Watkins JM, Harper JL, Dragun AE, et al. Incidence and prognostic factors for seroma development after MammoSite breast brachytherapy. Brachytherapy. 2008;7(4):305-309.
67. NSABP B-39, RTOG 0413: A randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. ClinAdvHematol Oncol. 2006;4(10):719-721.
68. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25(22):3259-3265.
69. Rosen PP, Fracchia AA, Urban JA, et al. "Residual" mammary carcinoma following simulated partial mastectomy. Cancer. 1975;35(3):739-747.
70. Ribeiro GG, Magee B, Swindell R, et al. The Christie Hospital breast conservation trial: an update at 8 years from inception. Clin Oncol (R Coll Radiol). 1993;5(5):278-283.
71. Dodwell DJ, Dyker K, Brown J, et al. A randomised study of whole-breast vs tumour-bed irradiation after local excision and axillary dissection for early breast cancer. Clin Oncol (R Coll Radiol). 2005;17(8):618-622.
72. Baglan KL, Sharpe MB, Jaffray D, et al. Accelerated partial breast irradiation using 3D conformal radiation therapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2003;55(2):302-311.
73. Chen PY, Wallace M, Mitchell C, et al. Four-year efficacy, cosmesis, and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76(4):991-997.
74. Rusthoven KE, Carter DL, Howell K, et al. Accelerated partial-breast intensity-modulated radiotherapy results in improved dose distribution when compared with three-dimensional treatment-planning techniques. Int J Radiat Oncol Biol Phys. 2008;70(1):296-302.
75. Moon SH, Shin KH, Kim TH, et al. Dosimetric comparison of four different external beam partial breast irradiation techniques: three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, helical tomotherapy, and proton beam therapy. Radiother Oncol. 2009;90(1):66-73.
76. Formenti SC, Truong MT, Goldberg JD, et al. Prone accelerated partial breast irradiation after breast-conserving surgery: preliminary clinical results and dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 2004;60(2):493-504.
77. Vicini F, Winter K, Straube W, et al. A phase I/II trial to evaluate three-dimensional conformal radiation therapy confined to the region of the lumpectomy cavity for Stage I/II breast carcinoma: initial report of feasibility and reproducibility of Radiation Therapy Oncology Group (RTOG) Study 0319. Int J Radiat Oncol Biol Phys. 2005;63(5):1531-1537.
78. Jagsi R, Ben-David MA, Moran JM, et al. Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76(1):71-78.
79. Hepel JT, Tokita M, MacAusland SG, et al. Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2009;75(5):1290-1296.
80. Leonard CE, Tallhamer M, Johnson T, et al. Clinical experience with image-guided radiotherapy in an accelerated partial breast intensity-modulated radiotherapy protocol. Int J Radiat Oncol Biol Phys. 2010;76(2):528-534.
81. Park Ck, Zhang G, Forster KM, et al. Evaluation of fiducial marker migration and respiratory-induced motion for image guided radiotherapy in accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2009; 75(3 suppl 1):S626-S627.
82. Pritz J, Zhang G, Forster KM, et al. Validating fiducial markers for image guided radiation therapy for accelerated partial breast irradiation in early stage breast cancer treatment. Int J Radiat Oncol Biol Phys. 2009; 75(3 suppl 1):S598-S599.
83. Wallner P, Arthur D, Bartelink H, et al. Workshop on partial breast irradiation: state of the art and the science, Bethesda, MD, December 8-10, 2002. Natl Cancer Inst. 2004;96(3):175-14.
84. Sauer R, Sautter-Bihl ML, Budach W, et al. Accelerated partial breast irradiation: consensus statement of 3 German Oncology societies. Cancer. 2007;110(6):1187-1194.
85. Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74(4):987-1001.